Posts

Posted on

Independent Research Ranks ZoomInfo the #1 GTM Connector in Anthropic’s Directory

Independent Research Ranks ZoomInfo the #1 GTM Connector in Anthropic’s Directory

Independent research tracking Anthropic’s connector directory found ZoomInfo in the top position every week of a nine-week study, a public measure of how widely revenue teams now reach verified go-to-market data through GTM.AI.

VANCOUVER, Wash.–(BUSINESS WIRE)–
ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, ranked as the number one go-to-market connector in Anthropic’s connector directory in a new independent benchmark from Send. The study, “The State of GTM Connectors,” tracked eleven GTM providers over nine consecutive weeks from July to September 2025 and placed ZoomInfo first in every one of them.

Send built the ranking on the directory’s own popularity score, which it calls the closest public signal to how widely each connector is actually used. Researchers polled the directory every minute across the study window, logging more than 100,000 snapshots in total and 3,610 for the eleven GTM providers studied. ZoomInfo finished at the top with a normalized index of 100.0, leading a competitive field in which the top providers stayed within roughly two index points of one another.

The connector runs on GTM.AI. The ZoomInfo connector in Anthropic’s directory is powered by GTM.AI, ZoomInfo’s headless GTM context layer and the API and Model Context Protocol home for AI agents. When a user asks Claude to research an account, size a market, or map a buying committee, GTM.AI is the context layer returning verified company and contact data behind the answer. Ranking first for nine straight weeks is a public measure of how much that context layer is already in use.

The result matters because agentic go-to-market work is only as accurate as the data underneath it. Roughly 70% of B2B contact data decays every year, and an AI assistant grounded in a stale export inherits every error in it. GTM.AI instead grounds those assistants in ZoomInfo’s verified data: more than 100 million companies, 500 million contacts, and billions of signals. That data is refreshed continuously rather than exported once and left to age.

One governed source across every AI surface. GTM.AI is the same context layer beneath ZoomInfo’s integrations across Claude, ChatGPT, Microsoft Copilot, Salesforce Agentforce, and HubSpot Breeze. Each surface reads from one governed source, so an organization’s entitlements, permissions, and data lineage stay intact wherever an agent runs. Authentication and governance remain tied to existing ZoomInfo permissions, and organizations keep visibility into what their agents access and where the data came from. That native, governed model is what separates a real context layer from a one-time data export.

The full benchmark is available from Send at send.co.

About ZoomInfo

ZoomInfo (NASDAQ: GTM), the all-in-one AI GTM platform, enables sales, marketing, and customer success teams to execute their go-to-market strategy with confidence. Powered by the industry’s most comprehensive B2B data, including more than 100 million companies, 500 million contacts, and billions of signals, ZoomInfo delivers the intelligence, automation, and integrations that modern revenue teams need to identify, engage, and convert their best buyers.

GTM.AI is ZoomInfo’s headless GTM context layer. It is the API and Model Context Protocol home for AI agents, powering integrations across Salesforce Agentforce, HubSpot Breeze, Microsoft Copilot, Claude, ChatGPT, and dozens more.

Learn more at zoominfo.com and gtm.ai.

Media contact:

Public Relations Team

ZoomInfo

[email protected]

KEYWORDS: Washington United States North America

INDUSTRY KEYWORDS: Apps/Applications Technology Venture Capital Marketing Communications Professional Services Digital Marketing Data Analytics Data Management Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

Donaldson Company Declares Quarterly Cash Dividend

Donaldson Company Declares Quarterly Cash Dividend

MINNEAPOLIS–(BUSINESS WIRE)–Donaldson Company, Inc. (NYSE: DCI) today announced its Board of Directors declared a regular cash dividend of 32.0 cents per share. The dividend is payable August 31st, 2026, to shareholders of record on August 17th, 2026. Donaldson is a member of the S&P High-Yield Dividend Aristocrats Index and calendar year 2025 marked the 30th consecutive year of annual dividend increases. The Company has paid a cash dividend every quarter for 70 years.

About Donaldson Company, Inc.

Founded in 1915, Donaldson (NYSE: DCI) is a global leader in technology-led filtration products and solutions, serving a broad range of industries and advanced markets. Diverse, skilled employees at over 150 locations on six continents partner with customers – from small business owners to R&D organizations and the world’s biggest OEM brands. Donaldson solves complex filtration challenges through three primary segments: Mobile Solutions, Industrial Solutions and Life Sciences. Additional information is available at www.Donaldson.com.

For more information, contact:
Sarika Dhadwal (952) 887-3753
[email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Research Genetics Oil/Gas Aerospace Manufacturing Energy Health Other Science Science

MEDIA:

Posted on

Illinois American Water Celebrates One Year of Expanded Income-Based Discount Program

PR Newswire


Program helps customers access affordable water and wastewater service

BELLEVILLE, Ill., July 31, 2026 /PRNewswire/ — Illinois American Water celebrated the one-year anniversary of the expansion of its Income-Based Discount Program, which has helped more than 4,000 Illinois households lower their monthly water and/or wastewater bills while continuing access to affordable water and/or wastewater services. Since the expansion, participating customers have saved an average of $40.00 monthly on their water and/or wastewater bills.

The program, expanded on July 1, 2025, increased eligibility for assistance to households with gross household incomes at or below 300% of the current Federal Poverty Income Guidelines (FPIG), allowing more customers to qualify for monthly bill discounts. Since the expansion, Illinois American Water has continued its commitment to helping customers manage expenses while maintaining access to safe, clean, reliable and affordable water and wastewater services.

“The expansion of the Illinois American Water Income-Based Discount Program is helping make water and wastewater service more affordable for customers who need financial help the most,” said Rebecca Losli, president of Illinois American Water. “Over the last year, thousands of customers have reduced their monthly bills to help them manage household expenses. We’re proud of the positive impact the program has made and remain committed to connecting eligible customers with available assistance.”

Illinois American Water’s Income-Based Discount Program provides monthly discounts ranging from 10% to 80% on water and wastewater bills based on gross household income and size. The program, administered by Dollar Energy Fund since August 2023, is available to eligible residential customers throughout Illinois.

Program Eligibility

Residential customers may qualify if their total gross household income is at or below 300% of the current FPIG. Eligible participants receive one of four discount levels based on their calculated FPIG level:

  • At or below 50% of FPIG – 80% discount
  • Between 51%-100% of FPIG – 65% discount
  • Between 101%-150% of FPIG – 40% discount
  • Between 151%-300% of FPIG – 10% discount

How Customers Can Apply

Customers can learn more about the program and begin the application process by:

Once approved, discounts are applied directly to eligible customer accounts as a monthly credit. Customers must recertify their eligibility annually to remain enrolled in the program.

“We encourage all customers who may be struggling with bill affordability to explore the assistance programs available,” Losli said.

In addition to the Income-Based Discount Program, Illinois American Water offers several customer assistance options, including H2O Help to Others™, payment arrangements and Budget Billing.

About American Water 
American Water (NYSE: AWK) is the largest regulated water and wastewater utility company in the United States. With a history dating back to 1886 and celebrating 140 years in 2026, We Keep Life Flowing® by providing safe, clean, reliable and affordable drinking water and wastewater services to approximately 14 million people with regulated operations in 14 states and on 18 military installations. American Water’s approximately 7,000 talented professionals leverage their significant expertise and the company’s national size and scale to achieve excellent outcomes for the benefit of customers, employees, investors and other stakeholders.

For more information, visit amwater.com and join American Water on LinkedIn, Facebook, X and Instagram.

About Illinois American Water

Illinois American Water, a subsidiary of American Water, is the largest regulated water utility in the state with approximately 600 dedicated employees working to provide safe, clean, reliable and affordable water and wastewater services to approximately 1.3 million people. American Water also operates a quality control and research laboratory in Belleville.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/illinois-american-water-celebrates-one-year-of-expanded-income-based-discount-program-302840300.html

SOURCE American Water

Posted on

AUGUST 4, 2026 PICS DEADLINE: PicS N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before August 4, 2026 Deadline

PR Newswire

SAN FRANCISCO, July 31, 2026 /PRNewswire/ — Hagens Berman alerts investors in PicS N.V. (NASDAQ: PICS) that a securities class action lawsuit has been filed, and the firm is actively investigating alleged misrepresentations and omissions in the company’s initial public offering disclosures regarding PicS’s credit underwriting practices.

Class Action


CLICK HERE TO SUBMIT YOUR PICS IPO LOSSES TO HBSS

Key PICS Class Action Case Details:

  • Defined Class / Relevant Investment Window: Investors who purchased or otherwise acquired PicS Class A common stock in and/or traceable to the company’s January 30, 2026 initial public offering (IPO)
  • Lead Plaintiff Deadline: Aug. 4, 2026
  • Contact Hagens Berman to discuss your rights:
    [email protected]

                                                                                      844-916-0895
                                                                                      www.hbsslaw.com/investor-fraud/pics 

Core Allegations in PicS Securities Class Action

The lawsuit alleges that PicS and certain top executives and underwriters made materially false and misleading statements in its IPO offering documents. Specifically, defendants allegedly failed to disclose that an internal review conducted in December 2025—weeks before the IPO—determined that the company’s historical credit evaluation policies and procedures were deficient and required urgent enhancements. These undisclosed deficiencies masked a severe deterioration in customer credit quality, heightened default risks, and a sharp spike in non-performing loan formations.

Post-IPO Disclosures and Market Reaction

Date

Post-IPO Disclosure

Stock Price Impact


March 19, 2026

PicS discloses Q4/FY 2025
results revealing pre-IPO credit
procedure deficiencies, R$590
million in Stage 3 loan
reclassifications, and a nearly
doubled default formation rate.


-22.5% single-day drop


(Plummeting $3.56 to close at
$12.27 per share)


June 2, 2026

Continued revelations of
escalating defaults (with Stage 3
loans reaching 13% of the
portfolio) drive shares down
further.


Over 50% total collapse


(Falling to a low of under $9.00
per share compared to the
$19.00 IPO price)

Hagens Berman’s Investigation

“We’re investigating whether PicS’ IPO documents misled investors by allegedly promoting its rapid credit expansion and proprietary AI-driven underwriting models as competitive advantages while omitting to disclose internal data showing portfolio degradation, as the suit contends,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the claims alleged in the pending lawsuit.

What Affected PICS Investors Can Do

If you purchased or acquired PicS Class A common stock in or traceable to the January 30, 2026 IPO and suffered losses, you have until August 4, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, or if you have knowledge that will assist the firm’s investigation, submit your information now »

If you’d like more information and answers to other frequently asked questions about the PicS case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding PicS should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/august-4-2026-pics-deadline-pics-nv-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-before-august-4-2026-deadline-302840284.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

Shareholders who lost money in shares of Hertz Global Holding, Inc. (NASDAQ: HTZ) should contact Wolf Haldenstein Immediately

PR Newswire

Lead Plaintiff Deadline September 22, 2026

NEW YORK, July 31, 2026 /PRNewswire/ — Wolf Haldenstein Adler Freeman & Herz LLP, a nationally recognized securities litigation law firm, informs investors that a securities fraud class action lawsuit has been filed against Hertz Global Holding, Inc. (NASDAQ: HTZ) (“Hertz” or the “Company”), on behalf of those who purchased or acquired Hertz common stock between May 7, 2026 and June 23, 2026, inclusive. 


PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION

Investors who purchased Hertz shares during the class period and suffered losses may be eligible to participate in the case, with the lead-plaintiff deadline set for September 22, 2026.

The Class Period begins on May 7, 2026, when Hertz issued a release announcing the Company’s Q1 2026 financial and operating results on Form 8-K, highlighting the Company’s “Strongest Revenue Growth in Three Years” and emphasizing its improved DPU metrics and solid liquidity and capital position. The following day, Hertz stated that the Company’s cash, liquidity facilities, and refinancing options would be sufficient to fund its operating activities and obligations for the next twelve months and for the near future.

On June 24, 2026, just weeks after assuring investors that its liquidity would carry the Company for at least twelve months, Hertz announced that a wholly owned indirect subsidiary intended to offer $300 million of Exchangeable Senior First-Lien Secured PIK Notes due 2030, together with a concurrent share-lending offering of more than 37 million shares of common stock from which the Company would receive no proceeds. Hertz simultaneously disclosed that “unexpected softness in the used car market” had caused losses on the sale of vehicles in May 2026 and would drive second quarter Adjusted Corporate EBITDA down to a range of just $50 million to $80 million.

On this news, the price of Hertz common stock declined more than 40%, closing at $3.00 per share on June 24, 2026.

The next day, the offering priced on still more dilutive terms, upsized to $350 million (up to $400 million) at a 6.75% coupon, with an exchange price of approximately $3.58 per share, and with the borrowed common stock sold to the public at just $2.70 per share.


WHY WOLF HALDENSTEIN?

This illustrious firm, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements. The law firm brings to the fore over 125 years of legal expertise in securities litigation and has a proven record of protecting the rights of investors.

We encourage all investors who have been affected or have information that will assist in our investigation, to contact Wolf Haldenstein Adler Freeman & Herz LLP.

There is no cost or obligation to speak with an attorney.

Contact:

Firm Website:
 Wolf Haldenstein Adler Freeman & Herz LLP

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-who-lost-money-in-shares-of-hertz-global-holding-inc-nasdaq-htz-should-contact-wolf-haldenstein-immediately-302840253.html

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP

Posted on

VRRM AUGUST 4, 2026 DEADLINE: Verra Mobility Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before August 4, 2026 Deadline

PR Newswire

SAN FRANCISCO, July 31, 2026 /PRNewswire/ — Hagens Berman Sobol Shapiro LLP alerts investors in Verra Mobility Corporation (NASDAQ: VRRM) that a securities fraud class action lawsuit has been filed, and the firm has broadened its ongoing investigation into the company following an abrupt leadership transition. Investors suffering substantial losses are encouraged to contact the firm now.

Class Action

Key VRRM Class Action Case Details

  • Class Period: Feb. 24, 2026 – May 26, 2026
  • Lead Plaintiff Deadline: Aug. 4, 2026
  • Contact Hagens Berman to discuss your rights, evaluate recovery options, or seek appointment as lead plaintiff:
    [email protected]

                                                                844-916-0895
                                                                www.hbsslaw.com/investor-fraud/vrrm

Core Allegations in Verra Mobility Lawsuit

The lawsuit alleges that Verra and certain executives made materially false and misleading statements and concealed critical adverse facts regarding the true state of the company’s relationship with Avis Budget Group. Defendants allegedly downplayed the risk of major rental car customers replacing Verra’s services with in-house or outsourced alternatives and misrepresented the likelihood of securing an Avis contract renewal.


Alleged Corrective Disclosure and Market Reaction

Date

Corrective Event

Stock Price Impact


May 26 – 27, 2026

Verra discloses the sudden Avis
contract termination notice,
slashes its 2026 outlook,
announces operational
restructuring, and initiates an
internal review of negotiations


-71.0% single-day crash


(Plummeting from $13.08 to
close at $3.85 on May 27,
wiping out roughly $1.4 billion
in market cap)

View our latest video summary of the allegations: youtu.be/FVEw5XACoGA

Hagens Berman’s Expanded Investigation

In addition to investigating the lawsuit’s claims that Verra misled investors about the stability of key revenue streams and contract negotiations, Hagens Berman’s expanded investigation also focuses on the sudden June 1, 2026 departure of long-time CEO David Roberts—ending a 12-year tenure—and whether this leadership vacuum is causally linked to the catastrophic loss of the Avis contract and subsequent disclosures.

“Our investigation is focused on the extent to which and when Verra and its executives knew that renegotiations with Avis were far from constructive, as the May 26 surprise reveals,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

What Affected VRRM Investors Can Do

If you purchased or acquired Verra Mobility common stock between February 24, 2026, and May 26, 2026, and suffered losses, you have until August 4, 2026, to ask the court to appoint you as lead plaintiff.

To learn more about your legal options, or if you have knowledge that will assist the firm’s investigation, submit your information to Hagens Berman.

If you’d like more information and answers to other frequently asked questions about the Verra case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Verra should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vrrm-august-4-2026-deadline-verra-mobility-corporation-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-before-august-4-2026-deadline-302840277.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

RBLX INVESTOR ALERT: Roblox Corporation (RBLX) Investors with Substantial Losses Have Opportunity to Lead the Roblox Class Action Lawsuit- August 7, 2026 Deadline

PR Newswire

SAN FRANCISCO, July 31, 2026 /PRNewswire/ — National shareholder rights firm Hagens Berman alerts investors in Roblox Corporation (NYSE: RBLX) that the alleged class period in the ongoing securities class action litigation has been expanded. A new lawsuit now covers investors who purchased or otherwise acquired Roblox common stock between October 31, 2024 through April 30, 2026, inclusive.

Class Action

National shareholder rights firm Hagens Berman is investigating the legal claims that Roblox and its co-defendants violated the federal securities laws. The firm encourages Roblox investors who suffered substantial losses to submit your losses now.

Class Period: Oct. 31, 2024 – Apr. 30, 2026
Lead Plaintiff Deadline: Aug. 7, 2026
Visit: www.hbsslaw.com/investor-fraud/rblx
Contact the Firm Now: [email protected]  
                                       844-916-0895
Roblox Corporation (RBLX) Securities Class Action:

The primary focus of the litigation is on the propriety of Roblox’s disclosures about its commitment toward protecting the safety of young users of its platform and the recent the impact on its business and prospects of the age-check verification rollout aimed at increasing safety within certain social features on its platform. The rollout began in November 2025.

During the Class Period, Roblox and its senior management have assured investors that “safety would be paramount[,]” “building safety into our products has been a huge effort[,]” and “[o]ur approach to safety includes multiple proactive measures as well as parental controls[.]” They have also emphasized that “b]ecause our Platform includes children aged 5 and over, our safety and civility policies are purpose-built to be strict.”

Investors slowly learned the truth through a series of disclosures beginning on October 30, 2025. That day, the Company revealed that it would be instituting enhanced age verification technology globally beginning in January 2026. On this news, the price of the Company’s common stock declined 16% from $133.74 per share to $113.00 per share, wiping out $13 billion in market value.

Then, on April 30, 2026, Roblox revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance (reflecting ongoing shrinkage in DAU growth), and severely cut its 2026 bookings growth midpoint from 24% to just 10%, investors glimpsed what was really going on.

Roblox said just 51% of its global DAUs age checked and also said that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.

“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

If you invested in Roblox and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.

If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.

Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rblx-investor-alert-roblox-corporation-rblx-investors-with-substantial-losses-have-opportunity-to-lead-the-roblox-class-action-lawsuit–august-7-2026-deadline-302840264.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

ERAS AUGUST 10, 2026 DEADLINE: Erasca, Inc. Investors Have Opportunity to Lead Shareholder Class Action Lawsuit – HBSS

PR Newswire

SAN FRANCISCO, July 31, 2026 /PRNewswire/ — Hagens Berman, a national shareholder rights firm, is actively investigating claims in a class action alleging securities law violations at Erasca, Inc. (NASDAQ: ERAS). The litigation alleges Erasca and its senior executives misled investors by providing a false narrative regarding the competitive advantage, safety profile, and intellectual property (IP) moat surrounding its lead oncology candidate, ERAS-0015.

Class Action

Hagens Berman urges Erasca investors who suffered significant losses to contact the firm now to discuss their rights. 

Class Period: Jan. 14, 2025 – Apr. 26, 2026
Lead Plaintiff Deadline: Aug. 10, 2026
Visit: www.hbsslaw.com/investor-fraud/eras
Contact the Firm Now: [email protected]
                                       844-916-0895

The Alleged Erasca (ERAS) Securities Fraud:

Erasca’s public disclosures throughout the class period (January 14, 2025 – April 26, 2026) repeatedly championed ERAS-0015 as a “best-in-class” pan-RAS molecular glue. The complaint alleges the company intentionally obfuscated critical risks by:

  • Improper Preclinical Comparisons: Allegedly using flawed cross-study analyses to claim superiority over competing therapies, such as Revolution Medicines’ RMC-6236, without a reasonable basis.
  • Concealing IP Disputes: Assuring investors that its IP was secure while allegedly failing to disclose that its practices exposed the company to significant patent infringement and trade secret misappropriation claims from Revolution Medicines.
  • Downplaying Safety Risks: Touting favorable safety results while allegedly failing to adequately disclose the risks associated with ERAS-0015 clinical trials, which later surfaced following a patient death.

The Truth Emerges:

The complaint alleges on April 27–28, 2026, the artificial inflation in Erasca’s stock price was removed following two major disclosures:

  1. Patent Infringement Allegations: The company disclosed a legal challenge from Revolution Medicines regarding patent infringement and trade secret misappropriation.
  2. Adverse Clinical Data: Erasca reported preliminary data including a patient death linked to the ERAS-0015 trial.

These disclosures triggered a sharp stock decline, with shares falling significantly and wiping out over $2.8 billion in market capitalization.

Hagens Berman’s Investigation

“We’re investigating whether Erasca may have intentionally misled investors about ERAS-0015’s safety profile and about a potential moat in its particular, highly competitive cancer treatment space,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.

Investor Rights and Lead Plaintiff Deadline

Investors who purchased or acquired Erasca common stock between January 14, 2025, and April 26, 2026, may be eligible to serve as the lead plaintiff in the ongoing litigation. The court-imposed deadline to move for appointment as lead plaintiff is August 10, 2026.

If you invested in Erasca and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »

If you’d like more information and answers to other frequently asked questions about the Erasca case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Erasca should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/eras-august-10-2026-deadline-erasca-inc-investors-have-opportunity-to-lead-shareholder-class-action-lawsuit–hbss-302840281.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS

PR Newswire

SAN FRANCISCO, July 31, 2026 /PRNewswire/ — Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company’s financial condition, revenue recognition, inventory distribution, and business practices.

Class Action


SUBMIT YOUR ADMA LOSSES TO HAGENS BERMAN NOW
 

Key ADMA Class Action Details


Alleged Wrongdoing in ADMA Biologics Lawsuit:

The lawsuit alleges that Defendants artificially inflated stock value by misrepresenting and failing to disclose that:

  • ADMA Biologics engaged in an undisclosed related party transaction;
  • ADMA Biologics used channel stuffing to create an appearance of revenue;
  • ADMA Biologics lacked adequate internal controls; and
  • As a result, Defendants’ statements about ADMA Biologics’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

The Truth Emerges and Market Reaction:

The suit alleges that the misstatements were revealed through several corrective disclosure events, which wiped out substantial shareholder value, exposing investors to severe financial harm.



                    Date



Corrective Event



Stock Price Impact



March 24, 2026

Culper Research publishes
short-seller report revealing
 channel stuffing, rebates, and
undisclosed related-party
distributor Genesis BioPharma,
triggering intense market sell-
offs over two trading days as
investors digest the revelations.



-31.6% combined

(March 24: Down 16.6% to
$11.33)

(March 25: Down 15.0% to
$9.63)

 



March 26, 2026

ADMA issues a press release
responding to the short-seller
report stating it was “taking
appropriate steps to review the
assertions,” alongside a stock
rating downgrade from Cantor
Fitzgerald, further eroding
investor confidence.



-13.9%

(Down $1.34 to close at $8.29)

 

Hagens Berman’s Investigation

“We’re investigation whether ADMA made false and misleading statements to investors concealing the reality of its distribution channels and financial reporting, as the suit alleges” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the lawsuit’s claims.

What Affected ADMA Investors Can Do

If you invested in ADMA and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your information to Hagens Berman »

If you’d like more information and answers to frequently asked questions about the ADMA case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding ADMA should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adma-august-10-2026-deadline-adma-biologics-inc-investors-have-opportunity-to-lead-class-action-lawsuit-hbss-302840271.html

SOURCE Hagens Berman Sobol Shapiro LLP

Posted on

Embecta Corp. (EMBC) Faces Securities Class Action Over Insulin Pen Needle Disclosure – Investors with Losses Encouraged to Contact HBSS

PR Newswire

SAN FRANCISCO, July 31, 2026 /PRNewswire/ — Hagens Berman, a leading national shareholder rights law firm, is conducting an investigation into Embecta Corp. (NASDAQ: EMBC) regarding alleged violations of federal securities laws. This investigation follows the recent filing of a class action lawsuit in the U.S. District Court for the District of New Jersey, which alleges that Embecta misrepresented the commercial stability of its insulin pen needle business.

Class Action

The firm encourages Embecta investors who suffered substantial losses to submit your losses now.

Class Period: Nov. 25, 2025 – May 4, 2026
Lead Plaintiff Deadline: Aug. 17, 2026
Visit: www.hbsslaw.com/investor-fraud/embc
Contact the Firm Now: [email protected] 
                                        844-916-0895

Focus of Embecta (EMBC) Securities Class Action:

The pending securities class action alleges that Embecta and its management misled investors regarding the stability and commercial strength of its core insulin pen needle business. The complaint contends that throughout the class period, Embecta repeatedly assured investors that its pen needle portfolio was “stable,” “resilient,” and “incredibly resolute.” Plaintiffs allege these statements were materially false and misleading because, in reality, the company was experiencing significant competitive share loss—particularly at a major customer—and broader market volume softness in the retail channel, all of which management allegedly knew or recklessly disregarded while reaffirming its positive financial guidance.

The truth behind these alleged misrepresentations was revealed on May 5, 2026, when in delivering its second-quarter fiscal 2026 financial results Embecta admitted to a massive revenue decline, citing specific headwinds in the U.S. pen needle market that contradicted its prior assurances. The company slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint and announced a drastic 93% reduction in its quarterly dividend, dropping it from $0.15 to $0.01 per share.

The market response to this news was immediate and severe, causing Embecta’s stock price to plummet 57.8% over a single trading day.

“We are investigating whether Embecta’s assurances were misleading, given that the company later reported a significant revenue decline and cited market volume softness,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation of the pending claims.

Investor Rights

Investors who purchased or acquired Embecta common stock during the Class Period are encouraged to contact our legal team.

If you’d like more information and answers to other frequently asked questions about the Embecta case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Embecta should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/embecta-corp-embc-faces-securities-class-action-over-insulin-pen-needle-disclosure–investors-with-losses-encouraged-to-contact-hbss-302840241.html

SOURCE Hagens Berman Sobol Shapiro LLP